Intratumoral immunotherapy of murine pheochromocytoma shows no age-dependent differences in its efficacy

Overview of attention for article published in Frontiers in endocrinology, May 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (64th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

twitter: 5 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 1 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 32,010 followers.

RT @NIHBrainTumor: Age is a leading risk factor for cancer development, but few new immunotherapies have been preclinically tested in older…

13 Jul 2023

Reply Repost Favourite

RT @NIHBrainTumor: Age is a leading risk factor for cancer development, but few new immunotherapies have been preclinically tested in older…

12 Jul 2023

Reply Repost Favourite

Age is a leading risk factor for cancer development, but few new immunotherapies have been preclinically tested in older murine models. A collaboration featuring Zhengping Zhuang and Herui Wang aims to change that. Via @FrontEndocrinol: https://t.co/YtqHTq

12 Jul 2023

Reply Repost Favourite

RT @KaterinaHadrava: Today is #Immune2Cancer Day! I am still kinda surprised how I ended in the field of cancer immunotherapy. It is tough!…

16 Jun 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.